

Biomarker Discovery in Blood and Urine

Liquid biopsy is a method to obtain biomarkers directly from body fluids such as blood or urine instead of solid tissue. It is a simple and non-invasive alternative to surgical biopsies.

With the growing recognition that circulating cell-free DNA (cfDNA) can provide critical information on diseases that are normally difficult to detect with standard approaches - including cancer - the interest in liquid biopsy methods for biomarker discovery and disease research is on the rise. In addition to cfDNA, exosomes are also a rich source of biomarkers that are amenable to the straightforward liquid biopsy approach.

To facilitate biomarker discovery in liquid biopsies, BioCat offers comprehensive tools for the complete workflow from the collection and preservation of blood or urine through the enrichment, purification and NGS analysis of

- Circulating cell-free DNA
- Circulating cell-free RNA
- Exosomal DNA and RNA

- Blood & Urine Collection and Preservation
- Circulating cell-free DNA Isolation
- Circulating cell-free RNA Isolation
- Exosome Isolation
- Exosomal DNA and RNA Isolation
- NGS DNA Library Preparation



Blood Collection and Preservation

Transport, Storage,
Plasma Separation

cfDNA Purification

Next Generation Sequencing

Detection and analysis of circulating cell-free DNA (cfDNA) in blood.

www.biocat.com/liquid-biopsy

BioCat GmbH

Technologiepark Im Neuenheimer Feld 584 D-69120 Heidelberg Tel.: +49 (0) 6221 71415 16 Fax: +49 (0) 6221 71415 29 E-Mail: info@biocat.com

www.biocat.com